Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
October 30, 2024 08:22 ET
|
Recursion Pharmaceuticals
Salt Lake City, UT, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will...
CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
August 08, 2024 14:41 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, Aug. 08, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Recursion (Nasdaq: RXRX), please note that in the first bullet under "Additional...
Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
August 08, 2024 07:30 ET
|
Recursion Pharmaceuticals
Recursion entered into a definitive agreement to combine with Exscientia to add its technology-enabled clinical pipeline, sector-leading partnerships, and precision chemistry capabilitiesRecursion...
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
August 08, 2024 01:32 ET
|
Recursion Pharmaceuticals
Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates...
Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
August 05, 2024 16:01 ET
|
Recursion Pharmaceuticals
Salt Lake City, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide...
Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock
June 26, 2024 22:07 ET
|
Recursion Pharmaceuticals
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug...
Recursion Announces Proposed Offering of Class A Common Stock
June 26, 2024 16:06 ET
|
Recursion Pharmaceuticals
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug...
Recursion to Participate in Upcoming Investor Conferences
June 03, 2024 09:00 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
May 29, 2024 15:27 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature...
Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
May 24, 2024 16:30 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, May 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Robert...